New BUSINESS Research Available. Click Here to Access Article(s): https://t.co/KHz5N6NU00
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @UMCGlobalSafety: How can we make the most of patient registries as useful data sources supporting regulatory decisions? Find out in @Dr…
RT @UMCGlobalSafety: How can we make the most of patient registries as useful data sources supporting regulatory decisions? Find out in @Dr…
RT @UMCGlobalSafety: How can we make the most of patient registries as useful data sources supporting regulatory decisions? Find out in @Dr…
How can we make the most of patient registries as useful data sources supporting regulatory decisions? Find out in @DrugSafetyJ: https://t.co/msQTMqrmac #MedicineSafety #pharmacovigilance https://t.co/SIvHkDBmNA
Patient registries can be a rich source of #MedicineSafety data – if they’re used. Find out more in @DrugSafetyJ: https://t.co/fyhJCp58jD
Los registros de pacientes pueden ser de gran utilidad para le regulación y vigilancia de los medicamentos, conoce más sobre este tema . . https://t.co/eWSL1Eaacp. https://t.co/KZVeuFrksB
How can we make the most of patient registries as useful data sources supporting regulatory decisions? #MedicineSafety #pharmacovigilance https://t.co/4hrVIbbJmd
Los registros de pacientes pueden ser de gran utilidad para le regulación y vigilancia de los medicamentos, conoce más sobre este tema . . https://t.co/2HGt1ggHgz https://t.co/bMOjdY2bxV
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @UMCGlobalSafety: Patient registries can be a rich source of #MedicineSafety data – if they’re used. Find out more in @DrugSafetyJ: http…
RT @TumainiMakole: Medicine Safety #AskMfamasia https://t.co/HBWRPpS8r6
Medicine Safety #AskMfamasia
RT @UMCGlobalSafety: Patient registries can be a rich source of #MedicineSafety data – if they’re used. Find out more in @DrugSafetyJ: http…
Patient registries can be a rich source of #MedicineSafety data – if they’re used. Find out more in @DrugSafetyJ: https://t.co/fyhJCp58jD https://t.co/KXHltN5c2F
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
RT @susiecharman: Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regul…
Data from the UK Cystic Fibrosis Registry @cftrust has been utilised in a number of drug safety studies to support regulatory submissions. Find out more about how we work with industry to help make CF medicines safer...https://t.co/bjygQlEFfI
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @iaiaraia: Very interesting article on the best way to use #PatientRegistries and why it is so important! Don’t miss it! https://t.co/c1…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @NephcEurope: Thank for listening to the voice of patients!! https://t.co/ttjcE01qZg
Thank for listening to the voice of patients!!
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @DTaruscio: Registries https://t.co/fhE9E4ceTP
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
Registries https://t.co/fhE9E4ceTP
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
Very interesting article on the best way to use #PatientRegistries and why it is so important! Don’t miss it!
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
In Drug Safety geven CBG’er Peter Mol en coauteurs aanbevelingen om beter gebruik te kunnen maken van patiëntenregisters. Zo leren we meer over de werking en veiligheid van medicijnen nadat ze op de markt zijn gekomen.
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
RT @EMA_News: How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉ht…
@grangeblanche @Formindep be my guest …
How can we increase the use of #PatientRegistries in regulatory assessments of #medicines 💊? Read more in this article: 👉https://t.co/rPFHa826bf https://t.co/N03ghqWiXN
RT @Nocebo88: Patient registries are potentially valuable sources of data for supporting regulatory decision-making but they are greatly un…
RT @Nocebo88: Patient registries are potentially valuable sources of data for supporting regulatory decision-making but they are greatly un…
Patient registries are potentially valuable sources of data for supporting regulatory decision-making but they are greatly underused owing to heterogeneity in registry design, the data collected and its quality, as well as to data sharing impediments. http
Patient Registries: An Underused Resource for Medicines Evaluation https://t.co/YEeCIMtrWv
Patient registries, ‘organised systems that use observational methods to collect uniform data on a population defined by a particular disease, condition, or exposure, and that is followed over time 患者登録簿は病気や容態や影響毎の観察記録の集合 https://t.co/sKxc5hsVFZ
'Patient registries may prove valuable in regulatory decisions, EMA study finds' Story via @endpts Study published in Drug Safety (https://t.co/CmetWjGJiy) #OpenAccess https://t.co/3nrSHpvgnK
RT @JACIE_EBMT: Patient Registries: An Underused Resource for Medicines Evaluation. new paper, open-access. @TheEBMT @CIBMTR @JKuball @CCha…
RT @JACIE_EBMT: Patient Registries: An Underused Resource for Medicines Evaluation. new paper, open-access. @TheEBMT @CIBMTR @JKuball @CCha…
RT @JACIE_EBMT: Patient Registries: An Underused Resource for Medicines Evaluation. new paper, open-access. @TheEBMT @CIBMTR @JKuball @CCha…
RT @JACIE_EBMT: Patient Registries: An Underused Resource for Medicines Evaluation. new paper, open-access. @TheEBMT @CIBMTR @JKuball @CCha…
RT @JACIE_EBMT: Patient Registries: An Underused Resource for Medicines Evaluation. new paper, open-access. @TheEBMT @CIBMTR @JKuball @CCha…
Patient Registries: An Underused Resource for Medicines Evaluation. new paper, open-access. @TheEBMT @CIBMTR @JKuball @CChabannon @EMA_News #registries https://t.co/2GMOmOHEHr
Explicit proposals, from a regulatory perspective, on operational methods for increasing the use of patient #registries in medicines regulation https://t.co/2wGh1UEHlr
"Patient Registries: An Underused Resource for Medicines Evaluation" by authors from @QMULWHRI @EMA_News @univgroningen 𝗗𝘂𝘁𝗰𝗵 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗕𝗼𝗮𝗿𝗱 #OpenAccess #Pharmacovigilance https://t.co/oHwFSvvUr9 https://t.co/EhZPByQEjj